Q1 2024 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2024-05-15 · accession 0000950123-24-005589
$1.52B
Reported value
7
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $1.03B | 67.6% | 9,666,038 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $250.0M | 16.4% | 25,001,856 | Common | SHARED |
| 68217N105 | — | Omega Therapeutics Inc | $106.7M | 7.00% | 29,225,579 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $85.0M | 5.58% | 12,674,120 | Common | SHARED |
| 24823R105 | DNLI | Denali Therapeutics Inc | $28.0M | 1.84% | 1,364,516 | Common | SHARED |
| 81750R102 | MCRB1EUR | Seres Therapeutics Inc | $17.9M | 1.17% | 23,117,045 | Common | SHARED |
| 87184Q206 | SYRS | Syros Pharmaceuticals Inc | $6.9M | 0.45% | 1,293,849 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.